We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+4.39%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$179M
AUM Growth
-$20.9M
(-10%)
Cap. Flow
-$34M
Cap. Flow
% of AUM
-18.99%
Top 10 Holdings %
Top 10 Hldgs %
92.09%
Holding
38
New
8
Increased
6
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Geron
GERN
|
+$1.34M |
| 2 |
Milestone Pharmaceuticals
MIST
|
+$1.06M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$1.02M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$741K |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$680K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Semtech
SMTC
|
+$55.1M |
| 2 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$2.6M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
+$1.95M |
| 4 |
Battalion Oil
BATL
|
+$1.41M |
| 5 |
Ardelyx
ARDX
|
+$898K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.67% |
| 2 | Consumer Discretionary | 0.89% |
| 3 | Financials | 0.47% |
| 4 | Energy | 0.06% |
| 5 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Battalion Oil
BATL
$31.9M
| $113K | 0.06% |
19,926
-202,256
| -91% | -$1.41M |
|
|
BFIIW
27
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
| $81.3K | 0.05% |
2,083,438
| – | – |
|
|
SPRB
28
Spruce Biosciences
SPRB
$118M
| $58.9K | 0.03% |
+1,000
| New | +$254K |
|
29
Microsoft
MSFT
$3.45T
| $42.1K | 0.02% |
100
| – | – |
|
30
Alphabet (Google) Class C
GOOG
$4.36T
| $15.2K | 0.01% |
100
| – | – |
|
|
31
Semtech
SMTC
$11B
| $385 | ﹤0.01% |
14
-2,577,841
| -100% | -$55.1M |
|
32
Aclaris Therapeutics
ACRS
$726M
| – | – |
-115,898
| Closed | -$122K |
|
33
Amylyx Pharmaceuticals
AMLX
$2.26B
| – | – |
-14,000
| Closed | -$206K |
|
34
Mirum Pharmaceuticals
MIRM
$6.46B
| – | – |
-13,500
| Closed | -$371K |
|
|
WHWK
35
Whitehawk Therapeutics
WHWK
$190M
| – | – |
-82,423
| Closed | -$166K |
|
|
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-82,425
| Closed | -$1.95M |
|
|
HARP
37
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| – | – |
-228,900
| Closed | -$2.6M |
|
Similar funds
PA
SR
SCTC
SRA
CP
B
BCPE
AE
Lion Point Capital's Q1 2024 Portfolio in Review
As of Q1 2024, Lion Point Capital held 38 positions worth $179M, down 10% from $200M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Lion Point Capital withdrew a net $34M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Harpoon Therapeutics, Inc. Common Stock, an estimated $2.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Lion Point Capital opened a new position in Geron worth $1.98M.
- Lion Point Capital's largest Q1 2024 buy was Geron: 600,000 shares worth $1.98M.
- Lion Point Capital added most to Milestone Pharmaceuticals in Q1 2024, an estimated $1.06M increase.
- Lion Point Capital's biggest Q1 2024 reduction was Semtech, cutting an estimated $55.1M.
- Lion Point Capital fully exited Harpoon Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $2.6M.
- Lion Point Capital's ten largest holdings make up 92% of its $179M portfolio in Q1 2024.
- Lion Point Capital opened 8 new positions and closed 6 in Q1 2024.
- Lion Point Capital's portfolio value fell 10% quarter-over-quarter to $179M.
Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.